Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Hugo Larose"'
Autor:
Hugo Larose, Myrto Lee, Jens Grueger, Amélie Anota, Nicolas Naïditch, Bruno Falissard, Mario Di Palma, Olivier Chassany, Laura Khalfallah-Neelz, Sarah Palazuelos-Muñoz, Aymeric Tetafort
Publikováno v:
Health Research Policy and Systems, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Objectives Patient’s health-related quality of life (HRQoL) is an important outcome measure that is considered by many payers and health technology assessment (HTA) bodies in the evaluation of treatments. We aimed to identify opportunities
Externí odkaz:
https://doaj.org/article/fc9bb172dbd546d6bf1e7b04e9e31049
Autor:
Matteo Villa, Federica Malighetti, Mario Mauri, Geeta G Sharma, Cosimo Lobello, Hugo Larose, Alessandra Pirola, Silvia Bombelli, Nicoletta Cordani, Luca Massimino, Šárka Pospíšilová, Suzanne D. Turner, Giorgio Inghirami, Lisa Pagani, Lucrezia Criscuolo, Fulvio Magni, Roberto Perego, Fabio Pagni, Rocco Piazza, Roberto Chiarle, Carlo Gambacorti-Passerini, Luca Mologni
Publikováno v:
HemaSphere, Vol 7, p e4206968 (2023)
Externí odkaz:
https://doaj.org/article/57ce5fe60c654f75b7e0fbc49a80ff02
Autor:
Myrto Lee, Hugo Larose, Martin Gräbeldinger, Jon Williams, Anne-Marie Baird, Susan Brown, Johannes Bruns, Russell Clark, Javier Cortes, Giuseppe Curigliano, Andrea Ferris, Louis P. Garrison, Y.K. Gupta, Ravindran Kanesvaran, Gary Lyman, Luca Pani, Zack Pemberton-Whiteley, Tomas Salmonson, Peter Sawicki, Barry Stein, Dong-Churl Suh, Galina Velikova, Jens Grueger
Publikováno v:
Health Policy Open, Vol 6, Iss , Pp 100116- (2024)
The move toward early detection and treatment of cancer presents challenges for value assessment using traditional endpoints. Current cancer management rarely considers the full economic and societal benefits of therapies. Our study used a modified D
Externí odkaz:
https://doaj.org/article/e4d6e9cf3a8d4b7d88dee937863945b9
Autor:
Hugo Larose, Nina Prokoph, Jamie D. Matthews, Michaela Schlederer, Sandra Högler, Ali F. Alsulami, Stephen P. Ducray, Edem Nuglozeh, Feroze M.S. Fazaludeen, Ahmed Elmouna, Monica Ceccon, Luca Mologni, Carlo Gambacorti-Passerini, Gerald Hoefler, Cosimo Lobello, Sarka Pospisilova, Andrea Janikova, Wilhelm Woessmann, Christine Damm-Welk, Martin Zimmermann, Alina Federova, Andrea Malone, Owen Smith, Mariusz Wasik, Giorgio Inghirami, Laurence Lamant, Tom L. Blundell, Wolfram Klapper, Olaf Merkel, G.A. Amos Burke, Shahid Mian, Ibraheem Ashankyty, Lukas Kenner, Suzanne D. Turner
Publikováno v:
Haematologica, Vol 106, Iss 6 (2020)
Patients diagnosed with Anaplastic Large Cell Lymphoma (ALCL) are still treated with toxic multi-agent chemotherapy and as many as 25-50% of patients relapse. To understand disease pathology and to uncover novel targets for therapy, Whole-Exome Seque
Externí odkaz:
https://doaj.org/article/ac9c68b0d9e342ba919d333429ab5aaa
Publikováno v:
Cancers, Vol 10, Iss 4, p 99 (2018)
Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL), remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy cures approximately 65–90% of patients. Over the last two decades, major ef
Externí odkaz:
https://doaj.org/article/82fd9f5ce1d7465c8e5b6a82f8c27134
Autor:
Geeta G. Sharma, Daniel Filip, Marek Mráz, Ivonne-Aidee Montes-Mojarro, Falko Fend, Šárka Pospíšilová, Andrea Janíková, David Belada, Boris Tichy, Nina Prokoph, Katerina Kamaradova, Vojtech Bystry, Luca Mologni, Hugo Larose, Carlo Gambacorti-Passerini, Suzanne D. Turner, Cosimo Lobello, Lenka Radová, Olaf Merkel, Huan-Chang Liang
Publikováno v:
Leukemia
Funder: European Union’s Horizon 2020 Marie Skłodowska – Curie Innovative Training Networks (ITN - ETN) under grant agreement No.: 675712European Union’s Horizon 2020 Marie Skłodowska – Curie Innovative Training Networks (ITN - ETN) under g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24b98fac453cb1fd3100dd08c6c8579
Publikováno v:
British Journal of Haematology. 185:1043-1054
Anaplastic large cell lymphoma (ALCL) is a T cell Non-Hodgkin Lymphoma that mainly presents in paediatric and young adult patients. The majority of cases express a chimeric fusion protein resulting in hyperactivation of anaplastic lymphoma kinase (AL
Autor:
JAIME VERDU AMOROS, Hugo Larose, Alicja Chybicka, Grażyna Wróbel, Jowita Frączkiewicz, Vikki Rand, Alexander Newman, Małgorzata Salamonowicz, Peixun Zhou, Bernarda Kazanowska
Publikováno v:
British Journal of Haematology. 182:5-109
Autor:
Gerald Hoefler, Jamie D. Matthews, Mariusz A. Wasik, Cosimo Lobello, Šárka Pospíšilová, Feroze Fazaludeen, Ahmed Elmouna, Monica Ceccon, Edem Nuglozeh, Martin Zimmermann, Michaela Schlederer, Hugo Larose, Christine Damm-Welk, Wilhelm Woessmann, Lukas Kenner, Giorgio Inghirami, Wolfram Klapper, Ibraheem Ashankyty, Olaf Merkel, Tom L. Blundell, Nina Prokoph, Shahid Mian, Luca Mologni, Laurence Lamant, Andrea Janíková, Andrea Malone, Alina Federova, G. A. Amos Burke, Suzanne D. Turner, Owen P. Smith, Carlo Gambacorti-Passerini, Sandra Högler, Ali F. Alsulami, Stephen P. Ducray
Publikováno v:
Haematologica
Patients diagnosed with anaplastic large cell lymphoma (ALCL) are still treated with toxic multi-agent chemotherapy and as many as 25-50% of patients relapse. To understand disease pathology and to uncover novel targets for therapy, we performed whol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bdffe2951211b6f92b06fdfe98cb310
http://hdl.handle.net/10281/336945
http://hdl.handle.net/10281/336945
Autor:
Geeta G. Sharma, Sorcha Forde, Hélène Pacquement, Ivonne A. Montes-Mojarro, Ralf Jauch, Wolfram Klapper, Cosimo Lobello, Liam C. Lee, Luca Mologni, Anne Lambilliotte, Suzanne D. Turner, Laurence Brugières, Roberto Chiarle, Stephen P. Ducray, Jamie D. Matthews, Birgit Geoerger, Shahid Pervez, Carlo Gambacorti-Passerini, Lukas Kenner, Šárka Pospíšilová, Klaas Bahnsen, Shi-Lu Luan, Nina Prokoph, Andrea Janíková, G. A. Amos Burke, Olaf Merkel, Huan-Chang Liang, Elif Karaca-Atabay, Hugo Larose, Wilhelm Woessmann, Qi Wang, Andishe Attarbaschi, Jack M. Monahan, Vikas Malik, Judith Landman-Parker, Isaia Barbieri, Gilles Vassal, Gudrun Schleiermacher, Nicola A. Probst
Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae853e045a135b7e317c7f6be0735d41
https://www.repository.cam.ac.uk/handle/1810/305799
https://www.repository.cam.ac.uk/handle/1810/305799